Covered recipient · General Payments record
NICHOLAS A WINGATE
Allopathic & Osteopathic Physicians Surgery Plastic and Reconstructive Surgery
General Payments · PY2021–2024
$692.20
- Reported across 47 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $229.43 | 19 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $193.73 | 17 |
| Galderma Laboratories, L.P. | $35.70 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (19)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.74 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106347720 | CMS |
| ABBVIE INC. | $5.15 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106347722 | CMS |
| ABBVIE INC. | $6.88 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106347724 | CMS |
| ABBVIE INC. | $3.98 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106347726 | CMS |
| ABBVIE INC. | $9.89 | 03/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106347728 | CMS |
| ABBVIE INC. | $16.89 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106347730 | CMS |
| ABBVIE INC. | $4.46 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106347732 | CMS |
| ABBVIE INC. | $2.50 | 05/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106347734 | CMS |
| ABBVIE INC. | $22.73 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106347736 | CMS |
| ABBVIE INC. | $13.06 | 06/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106347738 | CMS |
| ABBVIE INC. | $4.90 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106347740 | CMS |
| ABBVIE INC. | $9.01 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106347742 | CMS |
| ABBVIE INC. | $8.14 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106347744 | CMS |
| ABBVIE INC. | $12.03 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106347746 | CMS |
| ABBVIE INC. | $23.04 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106347748 | CMS |
| ABBVIE INC. | $5.41 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106347750 | CMS |
| ABBVIE INC. | $25.92 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106347752 | CMS |
| Galderma Laboratories, L.P. | $19.82 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145335669 | CMS |
| Galderma Laboratories, L.P. | $15.88 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145335671 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.